GTx, a biopharmaceutical company, has submitted a new drug application with the FDA for toremifene 80mg, an oral selective estrogen receptor modulator, for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy.
Read more:Â
GTx files new drug application for bone fracture therapy (Pharmaceutical Business Review)
0 Responses to “GTx files new drug application for bone fracture therapy (Pharmaceutical Business Review)”